



AstraZeneca




IAP4 Rec'd PCT/PTO 20 DEC 2005

*PCW*

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No.: 10/550,038	Applicant: Gravestock <i>et al</i>
Filing Date: September 21, 2005	Attorney Docket No.: 100869-1P US
Examiner: Not yet known	Group Art Unit : Not yet known
Customer No.: 44992	Confirmation No.: Not yet known
Title: ANTIBACTERIAL OXALIDINONES	

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on December 12, 2005

  
\_\_\_\_\_  
Signature  
Audrey Williams

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**INFORMATION DISCLOSURE STATEMENT**

Sir,

Applicants submit herewith a list of patents and publications pursuant to the duty to disclose in accordance with 37 C.F.R. § 1.56.

In accordance with 37 C.F.R. § 1.97 (g) and (h), the filing of this Information Disclosure Statement shall not be construed as a representation that a search has been made or that the information cited is material to patentability as defined in 37 C.F.R. § 1.56.

In accordance with the U.S. Patent Office's partial waiver of the requirement under 37 C.F.R. 1.98(a)(2)(i), only copies of the foreign patent documents and non-patent publications are enclosed.

RECEIVED  
OIPE/IAP

JAN 13 2006

### REMARKS

In accordance with the provisions of 37 C.F.R. 1.97, this statement is being filed before the mailing of the **first Office Action** on the merits.

It is respectfully requested that each of the patents and publications listed on the attached Forms SB08A and SB08B, and other information contained herein, be considered by the Examiner and made of record in this application.

Although Applicants believe no fees are due, the Commissioner is hereby authorized to charge any deficiency in the fees or credit any overpayment to deposit account No. 50-3231, referencing Attorney Docket No. 100869-1P US.

Respectfully submitted,



---

Name: Heidi M. Berven  
Dated: December 12, 2005  
Reg. No.: 48,951  
Phone No.: 781-839-4336

Global Intellectual Property, Patents  
AstraZeneca R&D Boston  
35, Gatehouse Drive  
Waltham, MA 02451

Enclosures: Form SB08A (1 page)  
Form SB08B (1 page)  
IPER  
Search Report  
Documents  
Postcard Receipt



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for Form 1449/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

**Complete if Known**

Application Number	10/550,038
Filing Date	September 21, 2005
First Named Inventor	Michael Barry Gravestock
Art Unit	Not yet assigned
Examiner Name	Not yet assigned
Attorney Docket No.	100869-1P US

SHEET of

**U.S. PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Document Number Number - Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear


**FOREIGN PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document Country Code <sup>3</sup> - Number <sup>4</sup> - Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
	AA	WO 01/81350 A1	11-01-2001	AstraZeneca AB AstraZeneca UK Limited		<input type="checkbox"/>
	AB	WO 03/035648 A1	05-01-2003	AstraZeneca AB AstraZeneca UK Limited		<input type="checkbox"/>
	AC	WO 03/072575 A1	09-04-2003	AstraZeneca AB AstraZeneca UK Limited		<input type="checkbox"/>
Examiner Signature					Date Considered	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kind Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



Under the Paperwork Reduction Act of 1995, no person is required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for Form 1449/PTO

Complete if Known

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Application Number	10/550,038
Filing Date	September 21, 2005
First Named Inventor	Michael Barry Gravestock
Art Unit	Not yet assigned
Examiner Name	Not yet assigned
Attorney Docket No.	100869-1P US

SHEET of

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	AD	LEE S C ET AL : "Carbon-carbon linked (pyrazolylphenyl)oxazolidinones with antibacterial activity against multiple drug resistant gram-positive and fastidious gram-negative bacteria" BIOORGANIC AND MEDICINAL CHEMISTRY, Vol . 9, no . 12, December 2001 (2001-12), pages 3243-3253, XP002283682 the whole document.	<input type="checkbox"/>
	AF	PHILILIPS O A ET AL : "Synthesis and antibacterial activity of 5-substituted oxazolidinones" BIOORGANIC AND MEDICINAL CHEMISTRY, vol . 11, no . 1, 2 January 2003 (2003-01-02), pages 35-41, XP002283683 the whole document.	<input type="checkbox"/>
			<input type="checkbox"/>
			<input type="checkbox"/>
			<input type="checkbox"/>
			<input type="checkbox"/>
			<input type="checkbox"/>
			<input type="checkbox"/>
			<input type="checkbox"/>
Examiner Signature		Date Considered	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.